CN102757941A - 甲型肝炎病毒株hav-zl2012,由其制备得到的疫苗及应用 - Google Patents
甲型肝炎病毒株hav-zl2012,由其制备得到的疫苗及应用 Download PDFInfo
- Publication number
- CN102757941A CN102757941A CN201210226440XA CN201210226440A CN102757941A CN 102757941 A CN102757941 A CN 102757941A CN 201210226440X A CN201210226440X A CN 201210226440XA CN 201210226440 A CN201210226440 A CN 201210226440A CN 102757941 A CN102757941 A CN 102757941A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- virus
- hav
- cell
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 43
- 241000709721 Hepatovirus A Species 0.000 title claims abstract description 39
- 241000700605 Viruses Species 0.000 claims abstract description 39
- 210000004027 cell Anatomy 0.000 claims abstract description 39
- 229940031551 inactivated vaccine Drugs 0.000 claims abstract description 27
- 210000001840 diploid cell Anatomy 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 229940124724 hepatitis-A vaccine Drugs 0.000 claims abstract description 17
- 208000005252 hepatitis A Diseases 0.000 claims description 37
- 238000011081 inoculation Methods 0.000 claims description 25
- 230000002238 attenuated effect Effects 0.000 claims description 24
- 210000003501 vero cell Anatomy 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 238000003757 reverse transcription PCR Methods 0.000 claims description 16
- 230000002458 infectious effect Effects 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000010257 thawing Methods 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000002356 single layer Substances 0.000 claims description 7
- 241000589945 Magnetospirillum magnetotacticum Species 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 244000309466 calf Species 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000002474 experimental method Methods 0.000 claims description 4
- 239000010410 layer Substances 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 239000013553 cell monolayer Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000001493 electron microscopy Methods 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 210000001728 clone cell Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 230000002441 reversible effect Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000002955 isolation Methods 0.000 abstract description 2
- 229940124590 live attenuated vaccine Drugs 0.000 abstract 1
- 229940023012 live-attenuated vaccine Drugs 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 241000282560 Macaca mulatta Species 0.000 description 15
- 241000282693 Cercopithecidae Species 0.000 description 14
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 238000013461 design Methods 0.000 description 7
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000002689 soil Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003067 hemagglutinative effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 101150039504 6 gene Proteins 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000011053 TCID50 method Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210226440.XA CN102757941B (zh) | 2012-06-29 | 2012-06-29 | 甲型肝炎病毒株hav-zl2012,由其制备得到的疫苗及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210226440.XA CN102757941B (zh) | 2012-06-29 | 2012-06-29 | 甲型肝炎病毒株hav-zl2012,由其制备得到的疫苗及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102757941A true CN102757941A (zh) | 2012-10-31 |
CN102757941B CN102757941B (zh) | 2014-01-29 |
Family
ID=47052593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210226440.XA Expired - Fee Related CN102757941B (zh) | 2012-06-29 | 2012-06-29 | 甲型肝炎病毒株hav-zl2012,由其制备得到的疫苗及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102757941B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105349500A (zh) * | 2015-11-26 | 2016-02-24 | 中国疾病预防控制中心病毒病预防控制所 | 一种新型甲型肝炎病毒株及其应用 |
CN109999187A (zh) * | 2019-05-09 | 2019-07-12 | 英诺激光科技股份有限公司 | 一种利用激光制备癌细胞疫苗的方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102277089B1 (ko) * | 2019-12-19 | 2021-07-14 | 에스케이바이오사이언스(주) | A형 간염 바이러스의 제조방법 및 상기의 방법에 따라 제조된 a형 간염 바이러스 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1047884A (zh) * | 1989-08-17 | 1990-12-19 | 浙江省医学科学院 | 甲型肝炎减毒活疫苗毒种(h2减毒株)及其制造方法 |
CN1012712B (zh) * | 1985-10-11 | 1991-06-05 | 美国政府(美国商务部代表) | 甲型肝炎病毒的纯化及其三次克隆 |
CN1337463A (zh) * | 2001-09-13 | 2002-02-27 | 浙江普康生物技术股份有限公司 | 甲肝病毒中国株和减毒株的培育及互补脱氧核糖核酸序列 |
-
2012
- 2012-06-29 CN CN201210226440.XA patent/CN102757941B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1012712B (zh) * | 1985-10-11 | 1991-06-05 | 美国政府(美国商务部代表) | 甲型肝炎病毒的纯化及其三次克隆 |
CN1047884A (zh) * | 1989-08-17 | 1990-12-19 | 浙江省医学科学院 | 甲型肝炎减毒活疫苗毒种(h2减毒株)及其制造方法 |
CN1337463A (zh) * | 2001-09-13 | 2002-02-27 | 浙江普康生物技术股份有限公司 | 甲肝病毒中国株和减毒株的培育及互补脱氧核糖核酸序列 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105349500A (zh) * | 2015-11-26 | 2016-02-24 | 中国疾病预防控制中心病毒病预防控制所 | 一种新型甲型肝炎病毒株及其应用 |
CN109999187A (zh) * | 2019-05-09 | 2019-07-12 | 英诺激光科技股份有限公司 | 一种利用激光制备癌细胞疫苗的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102757941B (zh) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103255163B (zh) | 一种ev71病毒样颗粒及其制备方法与应用 | |
CN104099301B (zh) | 柯萨奇病毒a16型病毒株、用途、疫苗及其制备方法 | |
CN112500458B (zh) | 鸡传染性法氏囊病病毒新型变异株亚单位疫苗、其制备方法及应用 | |
CN101695570A (zh) | 一种手足口病单、双价灭活疫苗及其制备方法 | |
CN102221618B (zh) | 猪瘟兔化弱毒标记疫苗毒株的构建及疫苗的制备方法 | |
CN108853490A (zh) | 一种预防手足口病和甲型肝炎的联合疫苗及其制备方法 | |
CN109536460A (zh) | 一种cv-a10病毒毒种及其人用灭活疫苗 | |
CN102757941B (zh) | 甲型肝炎病毒株hav-zl2012,由其制备得到的疫苗及应用 | |
CN102058882B (zh) | 一种制备甲型肝炎灭活疫苗的方法 | |
CN113564133B (zh) | 柯萨奇病毒a16型毒株及其免疫原性组合物和应用 | |
CN105112349A (zh) | 一种羊种布鲁氏菌分子标记疫苗株及其应用 | |
US10894081B2 (en) | Recombinant bivalent inactivated vaccine against foot-and-mouth disease virus, preparation method and use thereof | |
CN102348466A (zh) | 西尼罗病毒疫苗 | |
CN105039233B (zh) | 一种牛种布鲁氏菌分子标记疫苗株及其应用 | |
CN103333849A (zh) | 金黄色葡萄球菌突变株及其制备方法和应用 | |
CN106075423B (zh) | 一种预防手足口病的联合疫苗 | |
CN1022331C (zh) | 甲型肝炎减毒活疫苗毒种及其制造方法 | |
CN103127497B (zh) | 猪圆环病毒2型、肺炎支原体二联灭活疫苗及其制备方法 | |
CN101215552A (zh) | F基因型腮腺炎减毒毒种及其用途 | |
CN107557347A (zh) | 肠道病毒71型的新型病毒样颗粒、其制备方法及应用 | |
CN103160475B (zh) | 一种肠道病毒71型病毒株及其用途、疫苗和制备方法 | |
CN109602899B (zh) | 一种增强病毒抗原免疫原性的皮内注射技术及其在手足口病疫苗研究中的应用 | |
CN103160474B (zh) | 肠道病毒71型病毒株、疫苗、动物模型建立方法 | |
EP4272755A1 (en) | Combined vaccine for preventing hand, foot and mouth disease, preparation method therefor and use thereof | |
CN102210858B (zh) | 一种肠道病毒71型与甲型肝炎联合疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: INNER MONGOLIA BIGVET BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BEIJING JIANXIANG HEMU BIO-TECH CO., LTD. Effective date: 20140310 Free format text: FORMER OWNER: SHANXI LONGKEER BIOLOGICAL PHARMACEUTICAL CO., LTD. Effective date: 20140310 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100176 DAXING, BEIJING TO: 010176 HOHHOT, INNER MONGOLIA AUTONOMOUS REGION |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140310 Address after: 010176 the Inner Mongolia Autonomous Region Normal University and Hohhot County Shengle Economic Development Zone East Road Patentee after: INNER MONGOLIA BIGVET BIOTECHNOLOGY Co.,Ltd. Address before: 100176, Daxing District Yizhuang Economic Development Zone, Kangding street, No. 6, Paul Ji'an building, 2, Beijing Patentee before: Beijing Jianxiang Hemu Biological Technology Co.,Ltd. Patentee before: SHANXI LONGKER BIOLOGICAL PHARMACEUTICAL Corp. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140129 |
|
CF01 | Termination of patent right due to non-payment of annual fee |